Our investment in Adcentrx Therapeutics

Adcentrx Therapeutics (“Adcentrx”), a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announces the closing of a $38 million Series A+ financing. The round was led by Eight Roads Ventures, with participation from F-Prime Capital, ABio-X, Delta Capital, Trinity Innovation Fund, and other strategic investors. Life Venture Partners and Lighthouse Capital acted as Adcentrx's financial advisors. Adcentrx intends to use the proceeds from the financing to advance its proprietary ADC therapeutic pipeline into the clinic.

 

ADCs are a class of therapies that combine the target specificity of antibodies with the potency of conventional chemotherapy drugs. This class has revolutionized the treatment landscape in oncology with the potential to positively impact other serious diseases. Adcentrx differentiates itself by leveraging its team’s industry-leading experience in ADC drug development as well as deep expertise in chemistry and biology. The team has pioneered the development of an ADC technology toolbox addressing key components of protein conjugate design to solve challenges that arose in previous generations of ADCs. Adcentrx implements this optimized approach to fuel the development of a robust pipeline of first-in-class and best-in-class therapies. The company's lead candidate, ADRX-0706, is anticipated to enter a first-in-human Phase 1 clinical trial in the second half of 2023. Adcentrx is developing additional candidates in parallel with the goal of advancing at least one into the clinic each year.

 

“We are thrilled to have Eight Roads and our investors supporting our mission to bring innovative treatments to patients,” said Hui Li, Ph.D., Founder and CEO of Adcentrx. “Over the last two years, we have made significant progress advancing our emerging therapeutic pipeline that implements our proprietary and differentiated technology platform. This new round of funding from our investors will enable Adcentrx to quickly advance our safer and more efficacious conjugate therapies for patients in need. This year will be pivotal for Adcentrx, when we transition from the discovery stage into a clinical stage company.”

 

“ADCs as a therapeutic modality have flourished in recent years with a transformative inflow of active investment and strategic transactions. Adcentrx has demonstrated good potential of developing differentiated ADCs for unmet medical needs” commented Tao Huang, Ph.D., Principal of Eight Roads Ventures. “We are very excited to lead this round of financing to empower Adcentrx to accelerate its work in bringing new hope to patients in need.”

 

About Adcentrx Therapeutics

Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next-generation targeted therapies for improving patient treatment options.

シェア